Literature DB >> 490145

Deeper insight into HBsAg--anti-albumin antibody correlations.

R Lenkei, V T Babeş, A Mustea, I Dobre.   

Abstract

The presence and titers of anti-albumin antibodies (AAA)--ie, precipitins (AA-IP) and agglutinins (AA-Aggl)--and the serum concentrations of immunoglobulins and albumin were determined in 210 asymptomatic carriers of HBsAg grouped according to HBsAg titer and subtype. A different immunologic pattern was observed in the HBsAg/ad and HBsAg/ay carriers, the results suggesting an increased aggressivity for the HBsAg/ay subtype which was evident in subjects with lower HBs antigenemia and characterized by higher concentrations of IgG and IgM and rises in AA-P titers. A positive linear correlation was found between HBsAg and AA-Aggl titers; the carriage of HBsAg/ad was associated with significant higher values of AA-Aggl than of HBsAg/ay. These subtle correlations between HBsAg titer and subtype and AAA suggest that the human serum albumin (HSA) known to exist on the HBsAg particles may be similar in a modified form, to that representing AAA specificity.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 490145     DOI: 10.1002/jmv.1890040208

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  3 in total

1.  Anti-albumin antibodies in chronic liver diseases: diagnostic significance of these antibodies in patients with conventional or immunosuppressive therapy.

Authors:  R Lenkei; L Buligescu; I Belascu; D Pospai; I Dobre
Journal:  Clin Exp Immunol       Date:  1981-02       Impact factor: 4.330

2.  Specificities of albumin receptors and albumin antibodies.

Authors:  S N Thung; M A Gerber
Journal:  Infect Immun       Date:  1981-06       Impact factor: 3.441

3.  Failure to detect polyalbumin-binding sites on the woodchuck hepatitis virus surface antigen: implications for the pathogenesis of hepatitis B virus in humans.

Authors:  C J Pohl; P J Cote; R H Purcell; J L Gerin
Journal:  J Virol       Date:  1986-12       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.